Molecular minimal residual disease in acute myeloid leukemia

New England Journal of Medicine

Volumn 378, Issue 13, 2018, Pages 1189-1199

  Jongen Lavrencic, M ^a   Grob, T ^a   Hanekamp, D ^b   Kavelaars, F G ^a   Al Hinai, A ^a   Zeilemaker, A ^a   Erpelinck Verschueren, C A J ^a   Gradowska, P L ^a   Meijer, R ^a   Cloos, J ^b   Biemond, B J ^c   Graux, C ^e   Van Marwijk Kooy, M ^d   Manz, M G ^g   Pabst, T ^h   Passweg, J R ⁱ   Havelange, V ^f   Ossenkoppele, G J ^b   Sanders, M A ^a   Schuurhuis, G J ^b   Lowenberg, B ^a   Valk, P J M ^a   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ISALA HOSPITAL   (Netherlands)

^e CHU UCL Namur Site de Godinne   (Belgium)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; DNA;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASXL1 GENE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW EXAMINATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CEBPA GENE; CHROMOSOME ANALYSIS; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DNMT3A GENE; FEMALE; FLOW CYTOMETRY; FLT3 GENE; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HEMATOPOIESIS; HUMAN; IDH1 GENE; IDH2 GENE; INDUCTION CHEMOTHERAPY; KARYOTYPE; KIT GENE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; NPM1 GENE; NRAS GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PTPN11 GENE; RECURRENCE FREE SURVIVAL; RUNX1 GENE; STAG2 GENE; TET2 GENE; TP53 GENE; ADOLESCENT; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85044728706     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1716863     Document Type: Article

References (32)

1. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-74.
2. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136-52.
3. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209-21.
4. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424-47.
5. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood 2014; 124: 3345-55.
6. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia - current status and future perspectives. Curr Hematol Malig Rep 2015; 10: 132-44.
7. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia 2017; 31: 1482-90.
8. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374: 422-33.
9. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29: 2709-16.
10. Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia 2018; 32: 30-7.
11. Bhatnagar B, Eisfeld AK, Nicolet D, et al. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol 2016; 175: 226-36.
12. Pastore F, Levine RL. Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: ready for clinical practice? JAMA 2015; 314: 778-80.
13. Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA 2015; 314: 811-22.
14. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-87.
15. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-98.
16. Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017; 130: 742-52.
17. Shlush LI. Age-related clonal hematopoiesis. Blood 2018; 131: 496-504.
18. Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol 2017; 54: 43-50.
19. Buscarlet M, Provost S, Zada YF, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 2017; 130: 753-62.
20. Dutch-Belgian Cooperative Trial Group for Hematology-Oncology. Home page (http://www .hovon .nl).
21. Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leuke mia restricted to dose escalation of cytarabine. Blood 2012; 119: 5367-73.
22. Löwenberg B, Pabst T, Maertens J, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017; 129: 1636-45.
23. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889-97.
24. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood 2018 January 12 (Epub ahead of print).
25. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2011; 44: 23-31.
26. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
27. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-33.
28. McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 2015; 10: 1239-45.
29. Wong TNRG, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552-5.
30. Lindsley RCSW, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 2017; 376: 536-47.
31. Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations predict acute myeloid leukemia years before diagnosis. bioRxiv 2017 (https://www .biorxiv .org/content/early/2017/12/21/237941).
32. Ravandi F, Jorgensen J, Borthakur G, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 2017; 123: 426-35.